IP Library Patent Application 16875479
Patent Application
App. No. 16/875,479

Novel Group of STAT3 Pathway Inhibitors and Cancer Stem Cell Pathway Inhibitors

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/875,479
Abstract

The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such corn pounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof and to the pharmaceutical compositions of relevant compounds, and to the specific methods of administration of these compounds.

Claims (1)

1 . A method of inhibiting a cancer stem cell, the method comprising inhibiting at least some Stat3 pathway activity in the cancer stem cell through a Stat3 pathway inhibitor.

Assignments (2)
CHANGE OF NAME Recorded Sep 4, 2020
From: BOSTON BIOMEDICAL, INC.
To: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
Reel/Frame 053708/0635 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2020
From: LI, CHIANG JIA; ROGOFF, HARRY; LI, YOUZHI; LIU, JIFENG; LI, WEI
To: BOSTON BIOMEDICAL, INC.
Reel/Frame 052697/0001 →